医药生物行业报告（2026.3.16-2026.3.20）：海外CXO订单回暖，2026指引转向乐观

Industry Investment Rating - The industry investment rating is maintained at "Outperform" [2] Core Insights - The report highlights a recovery in overseas CXO orders, with optimistic guidance for 2026. The CDMO sector shows strong performance, while clinical CROs face challenges but are showing signs of improvement in orders [5][6][14] - The report emphasizes the differentiation in performance among companies, with CDMO firms like Lonza and Bachem demonstrating robust growth, while some clinical CROs like Fortrea and Charles River Laboratories are under pressure [14][15] - The report suggests a cautious yet optimistic outlook for the industry, with CDMO companies maintaining high capital expenditure and expanding capacity in emerging drug types such as ADCs, peptides, and oligonucleotides [25][28] Summary by Sections 1. Overseas CXO Orders Recovery and 2026 Guidance - The CXO industry shows a mixed performance in 2025, with CDMO companies exhibiting strong profitability growth, while clinical CROs face demand fluctuations and cost pressures [14] - Companies like Lonza and Bachem report significant revenue growth, driven by strong demand for their platforms [14][15] - There are positive signals in order performance, particularly in the second half of 2025, indicating a recovery in global biopharmaceutical investment [17][19] 2. Industry Views and Investment Recommendations - The report notes a downward trend in the A-share pharmaceutical sector, with a 2.77% decline, underperforming the CSI 300 index [32] - The innovative drug sector is experiencing a rebound, with increasing confidence in the competitiveness of domestic innovative drugs, supported by clinical data from key projects [36] - The report suggests focusing on investment opportunities in high-growth areas such as high-end imaging, surgical robots, and AI-driven medical devices [8] 3. Market Performance - The report details the performance of various sub-sectors within the pharmaceutical industry, highlighting the outperformance of the in vitro diagnostics sector and the underperformance of the hospital sector [7][32] - The report provides insights into the valuation changes across different pharmaceutical sub-industries, indicating a need for strategic investment in sectors showing resilience and growth potential [10][11]